je.st
news
Merck and Endocyte Announce Independent DSMB Recommends Vintafolide PROCEED Phase 3 Trial Be Stopped for Futility Following Interim Analysis
2014-05-02 14:00:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. & WEST LAFAYETTE, Ind. WHITEHOUSE STATION, N.J. & WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Endocyte, Inc. (NASDAQ:ECYT), today announced that the Data Safety Monitoring Board (DSMB) of the PROCEED trial has completed a pre-specified, interim futility analysis and the DSMB recommended that the trial be stopped because vintafolide did not demonstrate efficacy on the pre-specified outcome of Progression-Free Survival (PFS) in patients with platinum-resistant ovarian cancer. Language: English Contact: MerckMedia:Ian McConnell, +1 908-423-3046Claire Mulhearn, +1 908-423-7425orInvestors:Carol Ferguson, +1 908-423-4465Justin Holko, +1 908-423-5088orEndocyteMedia:Martina Schwarzkopf, +1 212-845-4292Tony Russo, +1 212-845-4251orInvestors:Stephanie Ascher, +1 212-362-1200 Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: ECYT Exchange: NASDAQ read more
Tags: following
analysis
independent
trial
Category:Biotechnology and Pharmaceuticals